This Article  • Full text  • PDF  • Correction  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Randomized Controlled Trial  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group

JAMA. 2002;288:2981-2997.

Context  Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown.

Objective  To determine whether treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic.

Design  The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, active-controlled clinical trial conducted from February 1994 through March 2002.

Setting and Participants  A total of 33 357 participants aged 55 years or older with hypertension and at least 1 other CHD risk factor from 623 North American centers.

Interventions  Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); amlodipine, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 years.

Main Outcome Measures  The primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intent-to-treat. Secondary outcomes were all-cause mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure [HF], and peripheral arterial disease).

Results  Mean follow-up was 4.9 years. The primary outcome occurred in 2956 participants, with no difference between treatments. Compared with chlorthalidone (6-year rate, 11.5%), the relative risks (RRs) were 0.98 (95% CI, 0.90-1.07) for amlodipine (6-year rate, 11.3%) and 0.99 (95% CI, 0.91-1.08) for lisinopril (6-year rate, 11.4%). Likewise, all-cause mortality did not differ between groups. Five-year systolic blood pressures were significantly higher in the amlodipine (0.8 mm Hg, P = .03) and lisinopril (2 mm Hg, P<.001) groups compared with chlorthalidone, and 5-year diastolic blood pressure was significantly lower with amlodipine (0.8 mm Hg, P<.001). For amlodipine vs chlorthalidone, secondary outcomes were similar except for a higher 6-year rate of HF with amlodipine (10.2% vs 7.7%; RR, 1.38; 95% CI, 1.25-1.52). For lisinopril vs chlorthalidone, lisinopril had higher 6-year rates of combined CVD (33.3% vs 30.9%; RR, 1.10; 95% CI, 1.05-1.16); stroke (6.3% vs 5.6%; RR, 1.15; 95% CI, 1.02-1.30); and HF (8.7% vs 7.7%; RR, 1.19; 95% CI, 1.07-1.31).

Conclusion  Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy.

ALLHAT Authors/Officers and Coordinators: Curt D. Furberg, MD, PhD; Jackson T. Wright, Jr, MD, PhD; Barry R. Davis, MD, PhD; Jeffrey A. Cutler, MD, MPH; Michael Alderman, MD; Henry Black, MD; William Cushman, MD; Richard Grimm, MD, PhD; L. Julian Haywood, MD; Frans Leenen, MD; Suzanne Oparil, MD; Jeffrey Probstfield, MD; Paul Whelton, MD, MSc; Chuke Nwachuku, MA, MPH; David Gordon, MD, PhD; Michael Proschan, PhD; Paula Einhorn, MD, MS; Charles E. Ford, PhD; Linda B. Piller, MD, MPH; J. Kay Dunn, PhD; David Goff, MD, PhD; Sara Pressel, MS; Judy Bettencourt, MPH; Barbara deLeon, BA; Lara M. Simpson, MS; Joe Blanton, MS; Therese Geraci, MSN, RN, CS; Sandra M. Walsh, RN; Christine Nelson, RN, BSN; Mahboob Rahman, MD; Anne Juratovac, RN; Robert Pospisil, RN; Lillian Carroll, RN; Sheila Sullivan, BA; Jeanne Russo, BSN; Gail Barone, RN; Rudy Christian, MPH; Sharon Feldman, MPH; Tracy Lucente, MPH; David Calhoun, MD; Kim Jenkins, MPH; Peggy McDowell, RN; Janice Johnson, BS; Connie Kingry, RN, BSN; Juan Alzate, MD; Karen L. Margolis, MD; Leslie Ann Holland-Klemme, BA; Brenda Jaeger; Jeffrey Williamson, MD, MHS; Gail Louis, RN; Pamela Ragusa, RN, BSN; Angela Williard, RN, BSN; R. L. Sue Ferguson, RN; Joanna Tanner; John Eckfeldt, MD, PhD; Richard Crow, MD; John Pelosi, RPh, MS.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Losartan vs Atenolol in Prevention of Stroke and Cardiovascular Disease
Sverre E. Kjeldsen
JAMA. 2003;289(6):701.
EXTRACT | FULL TEXT  

Reducing the Risk of Stroke—Reply
Sharon E. Straus, Finlay A. McAlister, and Sumit R. Majumdar
JAMA. 2003;289(15):1929.
EXTRACT | FULL TEXT  

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors
Taishiro Chikamori
JAMA. 2003;289(16):2066.
EXTRACT | FULL TEXT  

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors
Jan Laws Houghton
JAMA. 2003;289(16):2066.
EXTRACT | FULL TEXT  

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors
Christopher R. Palmer, Morris J. Brown, Giuseppe Mancia, and Luis M. Ruilope
JAMA. 2003;289(16):2066-2067.
EXTRACT | FULL TEXT  

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors
Franz H. Messerli and Michael A. Weber
JAMA. 2003;289(16):2067-2068.
EXTRACT | FULL TEXT  

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors
William Rifkin
JAMA. 2003;289(16):2068.
EXTRACT | FULL TEXT  

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors
H. T. Ong
JAMA. 2003;289(16):2068.
EXTRACT | FULL TEXT  

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors
Steven A. Yarows
JAMA. 2003;289(16):2068-2069.
EXTRACT | FULL TEXT  

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors—Reply
Jackson T. Wright, Jr, Barry R. Davis, and Jeffrey A. Cutler
JAMA. 2003;289(16):2069-2070.
EXTRACT | FULL TEXT  

The JNC 7 Hypertension Guidelines
Hean Teik Ong
JAMA. 2003;290(10):1312.
EXTRACT | FULL TEXT  

The JNC 7 Hypertension Guidelines—Reply
Aram V. Chobanian and Edward J. Roccella
JAMA. 2003;290(10):1314-1315.
EXTRACT | FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
Thomas Kaiser and Peter T. Sawicki
JAMA. 2003;290(23):3066.
EXTRACT | FULL TEXT  

Chlorthalidone vs Other Low-Dose Diuretics
Kenneth L. Choi, Dave Chua, and William J. Elliott
JAMA. 2004;292(15):1816-1817.
EXTRACT | FULL TEXT  

Chlorthalidone vs Other Low-Dose Diuretics—Reply
Bruce M. Psaty, Thomas Lumley, and Curt D. Furberg
JAMA. 2004;292(15):1817.
EXTRACT | FULL TEXT  

Erectile Dysfunction in Obese Men—Reply
Katherine Esposito, Francesco Giugliano, and Dario Giugliano
JAMA. 2004;292(20):2467.
EXTRACT | FULL TEXT  

Can Calcium Channel Blockers Preserve Renal Function Better Than Diuretics During Antihypertensive Treatment?—Reply
Peter W. de Leeuw, Luis M. Ruilope, and for the INSIGHT Investigators
Arch Intern Med. 2005;165(11):1312-1313.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
JAMA. 2002;288(23):2998-3007.
ABSTRACT | FULL TEXT  

The Verdict From ALLHAT—Thiazide Diuretics Are the Preferred Initial Therapy for Hypertension
Lawrence J. Appel
JAMA. 2002;288(23):3039-3042.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical Review: Is the Perioperative Use of {beta}-Blockers Still Recommended? A Critical Review of Recent Controversies
Domanski and Schwarz
J CARDIOVASC PHARMACOL THER 2009;14:258-268.
ABSTRACT  

Use of Diuretics in Patients with Hypertension
Ernst and Moser
NEJM 2009;361:2153-2164.
FULL TEXT  

Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Haywood et al.
J Am Coll Cardiol 2009;54:2023-2031.
ABSTRACT | FULL TEXT  

Physician and Pharmacist Collaboration to Improve Blood Pressure Control
Carter et al.
Arch Intern Med 2009;169:1996-2002.
ABSTRACT | FULL TEXT  

Fifty Years of Thiazide Diuretic Therapy for Hypertension
Moser and Feig
Arch Intern Med 2009;169:1851-1856.
ABSTRACT | FULL TEXT  

Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?
Ong
J Am Board Fam Med 2009;22:686-697.
ABSTRACT | FULL TEXT  

The Choice of Thiazide Diuretics: Why Chlorthalidone May Replace Hydrochlorothiazide
Kaplan
Hypertension 2009;54:951-953.
FULL TEXT  

Variation in Event Rates in Trials of Patients With Type 2 Diabetes
Psaty and Prentice
JAMA 2009;302:1698-1700.
FULL TEXT  

Beta-blockers as first-line antihypertensive therapy the crumbling continues.
Lavie et al.
J Am Coll Cardiol 2009;54:1162-1164.
FULL TEXT  

Beta-blockers for hypertension: Are they going out of style?
CHE et al.
Cleveland Clinic Journal of Medicine 2009;76:533-542.
ABSTRACT | FULL TEXT  

Whole grains and incident hypertension in men
Flint et al.
Am. J. Clin. Nutr. 2009;90:493-498.
ABSTRACT | FULL TEXT  

Possible contribution of the non-proteolytic activation of prorenin to the development of insulin resistance in fructose-fed rats
Nagai et al.
Exp Physiol 2009;94:1016-1023.
ABSTRACT | FULL TEXT  

Another Major Role for Dietary Sodium Reduction: Improving Blood Pressure Control in Patients With Resistant Hypertension
Appel
Hypertension 2009;54:444-446.
FULL TEXT  

The Hypertension Paradox -- More Uncontrolled Disease despite Improved Therapy
Chobanian
NEJM 2009;361:878-887.
FULL TEXT  

Response to Letter Regarding Article, "Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial"
Davis et al.
Circulation 2009;120:e32-e32.
FULL TEXT  

Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project
Bartholomew et al.
Clin Trials 2009;6:329-343.
ABSTRACT  

{beta}-Blocker Use for the Stages of Heart Failure
Klapholz
Mayo Clin Proc. 2009;84:718-729.
ABSTRACT | FULL TEXT  

Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach
O'Keefe et al.
Mayo Clin Proc. 2009;84:741-757.
ABSTRACT | FULL TEXT  

Thiazide Effects and Adverse Effects: Insights From Molecular Genetics
Ellison and Loffing
Hypertension 2009;54:196-202.
FULL TEXT  

Angiotensin-Converting Enzyme Inhibitors and Cognitive Decline in Older Adults With Hypertension: Results From the Cardiovascular Health Study
Sink et al.
Arch Intern Med 2009;169:1195-1202.
ABSTRACT | FULL TEXT  

Triple Fixed-Dose Combination Therapy: Back to the Past
Black
Hypertension 2009;54:19-22.
FULL TEXT  

Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs
Pogue et al.
Clin Trials 2009;6:239-251.
ABSTRACT  

A role for single-pill triple therapy in hypertension
Elijovich and Laffer
Ther Adv Cardiovasc Dis 2009;3:231-240.
ABSTRACT  

Renal and Brain Isoforms of WNK3 Have Opposite Effects on NCCT Expression
Glover et al.
J. Am. Soc. Nephrol. 2009;20:1314-1322.
ABSTRACT | FULL TEXT  

ALLHAT Findings Revisited in the Context of Subsequent Analyses, Other Trials, and Meta-analyses
Wright et al.
Arch Intern Med 2009;169:832-842.
ABSTRACT | FULL TEXT  

National Heart, Lung, and Blood Institute-Initiated Program "Interventions to Improve Hypertension Control Rates in African Americans": Background and Implementation
Einhorn
Circ Cardiovasc Qual Outcomes 2009;2:236-240.
FULL TEXT  

Insufficient Control of Blood Pressure and Incident Diabetes
Izzo et al.
Diabetes Care 2009;32:845-850.
ABSTRACT | FULL TEXT  

Hierarchy of Evidence: Where Observational Studies Fit in and Why We Need Them
Hoppe et al.
JBJS 2009;91:2-9.
ABSTRACT | FULL TEXT  

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
Hunt et al.
J Am Coll Cardiol 2009;53:e1-e90.
FULL TEXT  

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
2005 WRITING COMMITTEE MEMBERS et al.
Circulation 2009;119:e391-e479.
FULL TEXT  

Differential Effects of Chlorthalidone Versus Spironolactone on Muscle Sympathetic Nerve Activity in Hypertensive Patients
Menon et al.
J. Clin. Endocrinol. Metab. 2009;94:1361-1366.
ABSTRACT | FULL TEXT  

Antihypertensive Prescriptions for Newly Treated Patients Before and After the Main Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Results and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Guidelines
Muntner et al.
Hypertension 2009;53:617-623.
ABSTRACT | FULL TEXT  

Postgame Wrap of the Ultimate Blood Pressure Megatrial: Did It Score an ALLHAT Trick or Was It "Three Strikes and You're Out?"
Feldman and McAlister
Hypertension 2009;53:595-597.
FULL TEXT  

Comparative Effectiveness Research: The View From the NHLBI
Lauer
J Am Coll Cardiol 2009;53:1084-1086.
FULL TEXT  

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension
Parra et al.
NEJM 2009;360:1147-1150.
FULL TEXT  

Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis
Verdecchia et al.
Eur Heart J 2009;30:679-688.
ABSTRACT | FULL TEXT  

Prevention of congestive heart failure in high risk patients
Wachtell
Eur Heart J 2009;30:638-639.
FULL TEXT  

Prevention of risk factors: beta-blockade and hypertension
Mancia
Eur Heart J Suppl 2009;11:A3-A8.
ABSTRACT | FULL TEXT  

Overview of clinical research design
Hartung and Touchette
Am J Health Syst Pharm 2009;66:398-408.
ABSTRACT | FULL TEXT  

Urinary Angiotensinogen as a Novel Biomarker of the Intrarenal Renin-Angiotensin System Status in Hypertensive Patients
Kobori et al.
Hypertension 2009;53:344-350.
ABSTRACT | FULL TEXT  

Reexamining Misconceptions About {beta}-Blockers in Patients With Diabetes
McGill
Clin. Diabetes 2009;27:36-46.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes--2009
American Diabetes Association
Diabetes Care 2009;32:S13-S61.
FULL TEXT  

CHAPTER 13 Hypertension
Kjeldsen et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT | FULL TEXT  

CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome
Cosentino et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT | FULL TEXT  

Update on JAMA-EXPRESS: Rapid Review and Publication
Fontanarosa and DeAngelis
JAMA 2008;300:2920-2921.
FULL TEXT  

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Jamerson et al.
NEJM 2008;359:2417-2428.
ABSTRACT | FULL TEXT  

Does It Matter How Hypertension Is Controlled?
Chobanian
NEJM 2008;359:2485-2488.
FULL TEXT  

Review: BP-lowering drugs prevent cardiovascular events equally well in younger and older patients
Rich
Evid. Based Med. 2008;13:174-174.
FULL TEXT  

Resistant Hypertension An Overview of Evaluation and Treatment.
Sarafidis and Bakris
J Am Coll Cardiol 2008;52:1749-1757.
ABSTRACT | FULL TEXT  

Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
Davis et al.
Circulation 2008;118:2259-2267.
ABSTRACT | FULL TEXT  

Hypertension, Heart Failure, and Ejection Fraction
Little
Circulation 2008;118:2223-2223.
FULL TEXT  

Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial
DeKosky et al.
JAMA 2008;300:2253-2262.
ABSTRACT | FULL TEXT  

An 82-Year-Old Woman With Worsening Hypertension: Review of Renal Artery Stenosis
Rosenfield and Jaff
JAMA 2008;300:2036-2044.
ABSTRACT | FULL TEXT  

The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?
Hilgers and Mann
Nephrol Dial Transplant 2008;23:3389-3391.
FULL TEXT  

Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials
Turnbull et al.
Eur Heart J 2008;29:2669-2680.
ABSTRACT | FULL TEXT  

Blood Pressure Control with Amlodipine Add-on Therapy in Patients with Hypertension and Diabetes: Results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial
Kloner et al.
The Annals of Pharmacotherapy 2008;42:1552-1562.
ABSTRACT | FULL TEXT  

Dihydropiridine calcium-channel blockers and perioperative mortality in aortic aneurysm surgery
Kertai et al.
Br J Anaesth 2008;101:458-465.
ABSTRACT | FULL TEXT  

Epithelial Sodium Channel: Mendelian Versus Essential Hypertension
Rossier and Schild
Hypertension 2008;52:595-600.
FULL TEXT  

Hypertension, Heart Failure, and Beta-Adrenergic Blocking Drugs
Fowler
J Am Coll Cardiol 2008;52:1073-1075.
FULL TEXT  

Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies
Nallamothu et al.
Circulation 2008;118:1294-1303.
FULL TEXT  

Blood pressure guidelines - where are we now?
DTB 2008;46:65-69.
ABSTRACT | FULL TEXT  

Interpreting Results of Clinical Trials: A Conceptual Framework
Singh et al.
CJASN 2008;3:1246-1252.
FULL TEXT  

Treatment with angiotensin-converting enzyme inhibitors: insight into perindopril cardiovascular protection
Ferrari
Eur Heart J Suppl 2008;10:G13-G20.
ABSTRACT | FULL TEXT  

Which patients would benefit the most from the perindopril-amlodipine combination?
Danchin
Eur Heart J Suppl 2008;10:G29-G35.
ABSTRACT | FULL TEXT  

Should we prescribe diuretics for patients with prediabetes and hypertension?
Arroll et al.
BMJ 2008;337:a679-a679.
FULL TEXT  

Developing an automated speech-recognition telephone diabetes intervention
Goldman et al.
Int J Qual Health Care 2008;20:264-270.
ABSTRACT | FULL TEXT  

A Practical 'ABCDE' Approach to the Metabolic Syndrome
Blaha et al.
Mayo Clin Proc. 2008;83:932-943.
ABSTRACT | FULL TEXT  

High Perfusion Pressure Accelerates Renal Injury in Salt-Sensitive Hypertension
Mori et al.
J. Am. Soc. Nephrol. 2008;19:1472-1482.
ABSTRACT | FULL TEXT  

Heart Failure With Preserved Ejection Fraction: Treat Now by Treating Comorbidities
Shah and Gheorghiade
JAMA 2008;300:431-433.
FULL TEXT  

Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
Triplitt and Alvarez
Diabetes Spectr. 2008;21:177-189.
ABSTRACT | FULL TEXT  

Burden and Rates of Treatment and Control of Cardiovascular Disease Risk Factors in Obesity: The Framingham Heart Study
Molenaar et al.
Diabetes Care 2008;31:1367-1372.
ABSTRACT | FULL TEXT  

Thiazide-Induced Dysglycemia: Call for Research From a Working Group From the National Heart, Lung, and Blood Institute
Carter et al.
Hypertension 2008;52:30-36.
FULL TEXT  

Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research
Calhoun et al.
Circulation 2008;117:e510-e526.
ABSTRACT | FULL TEXT  

Review: The therapeutic role of RAS blockade in chronic heart failure
Werner and Bohm
Ther Adv Cardiovasc Dis 2008;2:167-177.
ABSTRACT  

Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research
Calhoun et al.
Hypertension 2008;51:1403-1419.
ABSTRACT | FULL TEXT  

Prevalence and incidence of hypertension from 1995 to 2005: a population-based study
Tu et al.
CMAJ 2008;178:1429-1435.
ABSTRACT | FULL TEXT  

Thiazide-Type Diuretics and {beta}-Adrenergic Blockers as First-Line Drug Treatments for Hypertension
Cutler and Davis
Circulation 2008;117:2691-2705.
FULL TEXT  

Reducing blood pressure in people of different ages
Staessen et al.
BMJ 2008;336:1080-1081.
FULL TEXT  

Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors
Solski and Longyhore
Am J Health Syst Pharm 2008;65:935-940.
ABSTRACT | FULL TEXT  

Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant et al.
J Am Coll Cardiol 2008;51:1865-1871.
ABSTRACT | FULL TEXT  

The role of percutaneous revascularization for renal artery stenosis
Dubel and Murphy
Vasc Med 2008;13:141-156.
ABSTRACT  

Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the Relative Influence of Antihypertensive Medication
Gupta et al.
Diabetes Care 2008;31:982-988.
ABSTRACT | FULL TEXT  

Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT | FULL TEXT  

Pulse Wave Velocity Is an Independent Predictor of the Longitudinal Increase in Systolic Blood Pressure and of Incident Hypertension in the Baltimore Longitudinal Study of Aging
Najjar et al.
J Am Coll Cardiol 2008;51:1377-1383.
ABSTRACT | FULL TEXT  

Review: {beta}-blockers for hypertension increase risk of new onset diabetes
Belknap
Evid. Based Med. 2008;13:50-50.
FULL TEXT  

Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study
Os et al.
Hypertension 2008;51:1103-1108.
ABSTRACT | FULL TEXT  

Trials That Matter: The Effect of a Fixed-Dose Combination of an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on the Complications of Type 2 Diabetes
Bakris and Berkwits
ANN INTERN MED 2008;148:400-401.
FULL TEXT  

Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus
McGuire et al.
Diabetes and Vascular Disease Research 2008;5:59-66.
ABSTRACT  

Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals
Stroup and Geddes
Schizophr Bull 2008;34:266-274.
ABSTRACT | FULL TEXT